GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

Data from the largest US Lyme disease registry suggests that 90% of PLD patients are excluded from clinical trials.

Novartis has recently announced that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) successfully ...

A ccording to preliminary estimates, Light Vehicle (LV) sales grew by 2.4% year-on-year (YoY) in December, to 1.51 million ...

Thanks to the expected introduction of several late-stage pipeline products. The type 1 diabetes (T1D) market across the ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Based on the data, China’s domestic market saw its second consecutive month of acceleration in November.

Consumer hesitation around taste remains a main challenge to successfully marketing alternative food and drink products, says GlobalData.

We recently compiled a list of the 10 Best Diabetes Stocks To Buy Under $10. In this article, we are going to take a look at ...

The prevalent cases of Alzheimer’s disease (AD) in the eight major markets globally are set to register an annual growth rate (AGR) of 4.08 per cent from 15.99 million in 2023 to 22.51 million in 2033 ...

About 422 million people worldwide have diabetes, according to the WHO, and most of them live in low- or middle-income ...

MET-3 is under clinical development by Nubiyota and currently in Phase II for Hypertriglyceridemia. According to GlobalData, Phase II drugs for Hypertriglyceridemia have a 52% phase transition success ...